SANDIMMUN IN THE TREATMENT OF CHRONIC GLO MERULONEPHRITIS WITH NEPHROTIC SYNDROME

Sandimmun was given to 11 patients (7 males and 4 females) aged 16-34 years with chronic glomerulonephritis (CGN) and nephrotic syndrome (NS ). Various morphological forms were revealed: minimal changes (MC), fo cal-segmentary glomerulosclerosis (FSGS), mesangiocapillary glomerulon ephritis (MCGS), membraneous glomerulonephritis (MGN), mesangioprolife rative glomerulonephritis (MPGN). They occurred in 1, 3, 2, 1 and 3 pa tients, respectively. Biopsy was not made in 1 case. The duration of t he disease varied from 1 to 4 years. Prior to this therapy 10 patients failed corticosteroids and cytostatics. Hypertension, high creatinine were registered in 3 and 5 patients, respectively. Sandimmun was give n for 2-18 months in a daily dose 3-5 mg/kg. Serum concentration 70-18 0 ng/ml. After 1 to 18 months of treatment nephrotic syndrome relieved in 1 MGN, 3 MPGN, 2 FSGS, 2 MCGS patients. The recurrences were repor ted in 4 patients after the drug discontinuation. Serious complication s were absent.